Drug intelligence / Profile preview

COVIGEN C20

Development stage: Unknown
Lead developer: Entos Pharmaceuticals
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

COVIGEN is an investigational DNA-based vaccine designed to protect against SARS-CoV-2, the virus responsible for COVID-19. The "C20" designation may refer to a specific formulation or batch, but there is no publicly available information confirming this as a unique product name or distinguishing it from the general COVIGEN vaccine. The vaccine is being evaluated for safety and immunogenicity in clinical trials[1]. As a DNA vaccine, it works by introducing genetic material encoding viral antigens into host cells, prompting an immune response without using live virus.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on COVIGEN C20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIGEN C20.

Explore the full profile